In vitro studies suggest that the oxidation of quinidine to 3-hydroxyquinidine is a specific marker reaction for CYP3A4 activity. To assess the possible use of this reaction as an in vivo marker of CYP3A4 activity, we studied the involvement of cytochromes CYP2C9, CYP2E1 and CYP3A4 in the in vivo oxidative metabolism of quinidine. Methods An open study of 30 healthy young male volunteers was performed. The pharmacokinetics of a 200 mg single oral dose of quinidine was studied before and during daily administration of 100 mg diclofenac, a CYP2C9 substrate (n=6); 200 mg disulfiram, an inhibitor of CYP2E1 (n=6); 100 mg itraconazole, an inhibitor of CYP3A4 (n=6); 250 ml single strength grapefruit juice twice daily, an inhibitor of CYP3A4 (n=6); 250 mg of erythromycin 4 times daily, an inhibitor of CYP3A4 (n=6). Probes of other enzyme activities, caffeine (CYP1A2), sparteine (CYP2D6), mephenytoin (CYP2C19), tolbutamide (CYP2C9) and cortisol (CYP3A4) were also studied. Results Concomitant administration of diclofenac reduced the partial clearance of quinidine by N-oxidation by 27%, while no effect was found for other pharmacokinetic parameters of quinidine. Concomitant administration of disulfiram did not alter any of the pharmacokinetic parameters of quinidine. Concomitant administration of itraconazole reduced quinidine total clearance, partial clearance by 3-hydroxylation and partial clearance by N-oxidation by 61, 84 and 73%, respectively. The renal clerance was reduced by 60% and the elimination half-life increased by 35%. Concomitant administration of grapefruit juice reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 15, 19 and 27%, respectively. The elimination half-life of quinidine was increased by 19%. The caffeine metabolic index was reduced by 25%. Concomitant administration of erythromycin reduced the total clearance of quinidine and its partial clearance by 3-hydroxylation and N-oxidation by 34, 50 and 33%, respectively. C max was increased by 39%. Conclusions The results confirm an important role for CYP3A4 in the oxidation of quinidine in vivo, and this applies particularly to the formation of 3-hydroxyquinidine. While a minor contribution of CYP2C9 to the N-oxidation of quinidine is possible, a major involvement of the CYP2C9 or CYP2E1 enzymes in the oxidation of quinidine in vivo is unlikely.
Introduction (CYP3A4) enzyme accounts for approximately 30% of the total human liver cytochrome P450 content, and The human cytochrome P450 system consists of a number of related enzymes which metabolize many among many drugs it oxidizes several calcium antagonists, protease-inhibitors, and macrolide antibiotics. Inter-characterize specific in vivo CYP3A4 biomarker reactions, by the Regional Ethics Committee and the Danish National Board of Health. Before inclusion, all volunteers notably the erythromycin breath test [2] , the oxidation of midazolam to 1∞-hydroxymidazolam [3] or endogenous were screened by physical examination, laboratory tests and electrocardiogram. cortisol metabolism [4] have been suggested among others. However all have proved to be of limited value in one way or another as discussed in detail by Watkins Study procedure [5] and Kivisto et al. [6] , and the quest continues for a readily available and convenient in vivo CYP3A4 assay.
Subjects were allocated consecutively by the time of inclusion to first a diclofenac group (n=6) and next to a Quinidine, a class 1A antiarrythmic, is metabolized primarily by CYP3A4 [7] . Studies of human liver disulfiram group (n=6), then to an itraconazole group (n=6), then to an erythromycin group (n=6) and finally microsomes and yeast recombinant P450 expression systems have shown that the formation of the (3S)-to a grapefruit juice group (n=6). No formal randomization procedure was performed. All volunteers completed 3-hydroxymetabolite is mediated almost exclusively by CYP3A4 [8] . We hypothesize following a low oral single two study phases with and without concomitant administration of drug or grapefruit juice according to their dose that the 3-hydroxylation of quinidine may serve as an in vivo biomarker reaction for CYP3A4 activity.
allocation. On study day 1 the volunteers took a single oral dose of 250 mg tolbutamide (Tolbutamid 'Dak', This study is one of a series of systematic interaction studies, which address the specificity of quinidine for the Nycomed DAK, Denmark), for assessment of CYP2C9 activity, at 08.00 h. Urine was collected for the next 6 h CYP3A4 enzyme in vivo, as high substrate specificity is obviously an essential feature of any biomarker reaction. and a sample (10 ml) was frozen at −20°C until analysis. Blood glucose was measured after 6 h. On study day 2 Previously a role for CYP2D6 in the oxidation of quinidine has been excluded [9] and a major role for the all of the volunteers took 100 mg of sparteine sulphate (Depasan, Giulini Pharma GMBH, Germany), 100 mg CYP1A2 and CYP2C19 enzymes seems unlikely [10] . The CYP2C9 enzyme is involved in the oxidation of of mephenytoin (Mesantoin, Sandoz Pharmaceuticals Corporation, USA) and 200 mg of caffeine (Koffein most nonsteroid anti-inflammatory drugs and tolbutamide. As the CYP2C9 inhibitor of choice, sulphaphena-'Dak', Nycomed DAK, Denmark) orally at 08.00 h, for the assessment of CYP2D6, CYP2C19 and CYP1A2 zole, is now only available for in vitro studies, we chose diclofenac as a putative competitive inhibitor of CYP2C9.
activities, respectively. It has been demonstrated, that the simultaneous administration of low dose biomarker drugs Diclofenac is a substate with high affinity for this enzyme [11] , and has been shown to inhibit the metabolism of does not influence the outcome of their respective metabolic indices [19] . Urine was collected for 12 h and other CYP2C9 substrates in vitro [12] . The reductive product of disulfiram, diethylthiocarbamate, is a well three 10 ml samples were frozen at −20°C until analysis. A blood sample (10 ml) was drawn after 6 h and the documented potent inhibitor of CYP2E1 [13, 14] . Grapefruit juice is an inhibitor of intestinal CYP3A4 plasma was separated by centrifugation (10 min, 7000 g) and frozen at −20°C until analysis. On study day 3, [15], itraconazole is a potent inhibitor of CYP3A4 [16, 17] , and erythromycin also inhibits CYP3A4 [18] . We following an overnight fast from midnight, the volunteers took a single oral dose of quinidine sulphate (200 mg ) hypothesized that concomitant administration of diclofenac or disulfiram would not affect the oxidative (Kinidin 'Dak', Nycomed DAK, Denmark), equal to 511 mmol quinidine. Blood samples (10 ml) were colmetabolism of quinidine but that grapefruit juice, itraconazole and erythromycin indeed would inhibit the lected at t=0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 24 and 48 h. Plasma was separated by centrifugation (10 min, 7000 g) oxidative metabolism of quinidine, albeit by different orders of magnitude. The purpose of the present study is and frozen at −20°C until analysis. Volunteers were allowed normal meals after the blood sample at t=1 h to confirm that the 3-hydroxylation of quinidine is mediated by CYP3A4 in vivo.
was drawn. Urine was collected at intervals of 0-12, 12-24 and 24-48 h. A sample (10 ml) from each period was frozen at −20°C until analysis. Following a washout Methods period of 6-8 weeks, the volunteers according to their allocation group took: 100 mg diclofenac (Voltaren Subjects Retard, Ciba-Geigy, Denmark) daily at 08.00 h on study days −1, 0, 1, 2, 3 and 4; 200 mg disulfiram (Antabus,  This was an open study of 30 young healthy male  volunteers between 20 and 35 years of age, all phenotyped Dumex-Alpharma, Denmark) daily at 08.00 h on study days −2, −1, 0, 1, 2, 3 and 4; 100 mg itraconazole as extensive metabolizers of sparteine (metabolic ratio <20) and mephenytoin (S/R ratio <0.5). All volunteers (Sporanox, Janssen-Cilag, Denmark) daily at 08.00 h on study days −2, −1, 0, 1, 2, 3 and 4; 250 mg gave written informed consent. The study was approved erythromycin (Erycin, Nycomed Dak, Denmark) four and an IBM personal computer. Separations were achieved using a Spherisorb S5 Phenyl, 5 mm times daily at 08.00, 12.00, 18.00 and 22.00 h, on study days −2, −1, 0, 1, 2, 3, and 4; 250 ml single strength (250*4.6 mm i.d.) column. The limits of quantification, based on coefficients of variation of less than grapefruit juice (Grapefrugt Juice, Rynkeby, Denmark) twice daily at 08.00 and 20.00 h on study days −2, −1, 20%, were 1.25 mm for tolbutamide, 0.75 mm for 4-hydroxytolbutamide and 2 mm for carboxytolbutamide. 0, 1, 2, 3 and 4. The initial study procedures with the biomarker reactions of tolbutamide, sparteine, mepheny-
The coefficient of variation was in the range of 4.0-4.7% for all three compounds for tolbutamide and hydroxytoltoin, caffeine and endogenous cortisol followed by the single-dose pharmacokinetics of quinidine were repeated butamide concentrations between 6 and 12 mm and for carboxytolbutamide concentrations between 24 and on days 1-4. During the study, the volunteers refrained from any other medication, alcohol or grapefruit juice.
48 mm. As the concentration of tolbutamide in urine was mostly below the limits of quantification, a metabolic Consumption of coffee and xanthine containing foods was not allowed for a period of 48 h before and during ratio could not be assessed. To get an index of CYP2C9 activity, we chose to calculate a tolbutamide metabolic the 12 h of urine collection following oral administration of caffeine. The volunteers were asked specifically about index as: adverse events on a daily basis during medication.
Tolbutamide metabolic index= Following treatment with diclofenac, disulfiram, itraconazole, erythromycin and grapefruit juice control laboratory tests were performed.
(amount of hydroxytolbutamide in urine) +(amount of carboxytolbutamide in urine) dose of tolbutamide
Quinidine and metabolites
As subject compliance was 100% and tolbutamide is Quinidine, 3-hydroxyquinidine and quinidine-N-oxide almost completely bioavailable, this index, while not in plasma and urine were analysed by means of h.p.l.c. validated as the ratio used by Veronese and coworkers methods described previously [20] . The limit of quantifi-
[21] (who used a ratio of the sum of the urine cation was 5 nm for quinidine, 3 nm for 3-hydroxyconcentrations of the two tolbutamide metabolites to quinidine and 4 nm for quinidine-N-oxide. The the concentration of urine tolbutamide in a 6 h urine coefficient of variation was in the range of 3-6% at sample following an oral single dose of 500 mg tolconcentrations between 0.25 and 10 mm for all three butamide), may be useful in assessing effects on compounds.
CYP2C9 activity.
Tolbutamide and metabolites
Sparteine and metabolites A method for the quantification of tolbutamide, Sparteine and its metabolites, 2,3-and 5,6 dehydrospar-4-hydroxytolbutamide and the secondary metabolite teine were analysed by means of gas chromatography carboxytolbutamide in urine was developed. Briefly; [22] , and the sparteine metabolic ratio was calculated as: urine samples (1 ml) were added 25 ml of 0.01 m internal Sparteine MR= standard, chlorpropamide, and 30 ml 2 m HCl and 4 ml of tert.-butyl methyl ether. The mixture was shaken for 30 min, and the phases separated by 10 min of centrifu-% of dose excreted as sparteine in 12 h urine % of dose excreted as 2,3 and 5,6-dehydrosparteine in 12 h urine gation at 1100 g. The tubes were stored at −30°C until the aqueous phase was frozen. The organic phase was transferred to conical glass tubes and evaporated to dryness under nitrogen at 40°C. The residue was reconstituted Mephenytoin in 1 ml of a mobile phase consisting of a 23577% (v/v) mixture of methanol and 0.01 m sodium acetate buffer
The chromatographic peak areas of S-and adjusted to a pH of 3.0 with 60% perchloric acid. A R-mephenytoin in 12 h urine were assayed by means of sample of 100 ml was transferred to h.p.l.c. vials. The gas chromatography [23] , and the S/R ratio was injection volume was 20 ml. Chromatography was percalculated as: formed using Merck-Hitachi instruments: an AS-2000 A Mephenytoin S/R= autosampler with a 100 l injector loop, a L-5025 column thermostat, a L-6200 intelligent Pump and a L-4250 UV-VIS Detector.The system was controlled through a chromatographic peak area of (S)-mephenytoin chromatographic peak area of (R)-mephenytoin D-6000 interface module h.p.l.c. System Manager (HSM) CL (q I 3OH−q ) = Caffeine and metabolite Caffeine and 1.7 dimethylxanthine were analysed by amount of 3-hydroxyquinidine in urine (0,48 h) AUC(0,48 h) means of h.p.l.c. as described by Rasmussen [24] . The limits of quantification were 1.2 mm and 0.3 mm for Partial clearance by N-oxidation was calculated as: caffeine and 1,7 dimethylxanthine, respectively. The CL (q I q−No) = coefficients of variation were in the range of 3-8% for both compounds at concentrations between 4 and 30 mm.
amount of quinidine N-oxide in urine (0,48 h) AUC(0,48 h) The caffeine metabolic ratio was calculated according to Fuhr [25] as:
Residual clearance was calculated as: Caffeine metabolic ratio=
plasma concentration of 1,7 dimethylxanthine plasma concentration of caffeine The terminal elimination half-life of quinidine was calculated as:
Cortisol and metabolite
where l z is the terminal slope of the log plasma Cortisol and 6b-hydroxycortisol were analysed by means concentration vs time curve. of h.p.l.c. [26] . The limit of quantification was 14 nm for cortisol and 87 nm for 6b-hydroxycortisol. The coefficient Statistical analyses of variation was in the range of 5-10% for both compounds. The metabolic ratio was calculated according Data are presented as median and range. Statistical test to Ged [4] as:
values are Hodges-Lehmann estimates of median differences with exact 95% confidence intervals. Inter-group Cortisol metabolic ratio= comparison was made by the median test. Differences were considered statistically significant when the 95% concentration in the urine of 6b-hydroxycortisol concentration in the urine of cortisol confidence intervals excluded zero. Statistical analyses were performed using the software packages SPSS 7.5 for Windows (SPSS Inc., USA) and StatXact 3 (Cytel Software Corporation, USA).
Pharmacokinetic analyses
Results All pharmacokinetic parameters were calculated using noncompartmental methods with the software package All volunteers completed the study. No side-effects were Winnonlin Standard Version 1.5 (Scientific Consulting reported during administration of diclofenac. During Inc., USA). The area under the plasma concentrationadministration of disulfiram, one volunteer had intermittime curves of quinidine (AUC) and its metabolites were tent diarrhoea, and another volunteer complained of calculated using the linear trapezoidal method with slight abdominal discomfort. Side-effects during adminisextrapolation to infinity. Values of peak concentration tration of itraconazole were nausea (one subject) and (C max ) and time to reach peak concentration (t max ) were intermittent headache (one subject). Side-effects during noted directly.
administration of erythromycin was abdominal discomfort The apparent oral clearance of quinidine was calculated (one subject), while no side-effects were seen during as: administration of grapefruit juice. All control laboratory tests were within normal values. Six hours after administration of tolbutamide blood glucose concentrations were CL= Dose AUC(0,2) within the range of 2.6-5.9 mm, without any subjective or objective signs of hypoglycaemia, in all subjects. The Quinidine renal clearance was calculated as:
only other side-effects noted were slight degrees of headache and irritability due to abstinence from caffeine. CL (r) = amount of quinidine in urine (0,48 h)
The study results with the pharmacokinetic parameters of quinidine and the biomarker reactions are summarized in Tables 1 and 2 . Partial clearance by 3-hydroxylation was calculated as: parameters of quinidine were unaffected by concomitant administration of diclofenac. This interaction must have Effect of itraconazole occurred at the metabolic level since the renal clearance was unaffected. As diclofenac is a substrate and hence a The median total oral clearance of quinidine and the partial clearances by 3-hydroxylation and N-oxidation putative competitive inhibitor of CYP2C9 [11, 12] , these results are consistant with results from in vitro studies, in were significantly reduced by 61, 84 and 73%, respectively. The median elimination half life of quinidine which up to 23% of the quinidine N-oxidation was accounted for by CYP2C9 [8] . The fact that an effect on increased 35%, while no statistically significant changes was found for C max . The median C max of the putative marker reaction of CYP2C9 was not seen, could be that the tolbutamide index used here is not a 3-hydroxyquinidine decreased from 0.3 to 0.1 mm (median difference: −0.2 mm; 95% confidence intervals valid marker of this reaction. Alternatively, a type 2 error due to a small sample size and the intraindividual of the difference: [−0.6, −0.08 mm]), while the median quinidine N-oxide C max decreased from 0.6 to 0.2 mm variability of this index is a possibility. As no pharmacokinetic parameters other than the partial clearance by N-(median difference: −0.5 mm; 95% confidence intervals of the difference: [−1.1, −0.2 mm]). The renal clearance oxidation was affected, the results mitigate against an involvement of CYP2C9 in the formation of the of quinidine was significantly reduced by a median 60%. No statistically significant effects on the biomarker 3-hydroxymetabolite of quinidine. The effect on the sparteine: dehydrosparteine metabolic ratio suggesting an reactions were found.
induction of CYP2D6 is difficult to explain as anything other than a statistical type 1 error, as CYP2D6 is Effect of erythromycin generally believed to be uninducible. Administration of disulfiram did not alter any of the pharmacokinetic The median total apparent oral clearance of quinidine, clearance by 3-hydroxylation and by N-oxidation were parameters of quinidine. In vitro, less than 2% of the oxidative metabolism of quinidine was accounted for by significantly decreased by 34, 50 and 33%, respectively. The median C max increased significantly by 39%. The CYP2E1, and accordingly a very high K i of 248 mm for the reductive product of disulfiram, diethylthiocarbamate, median elimination half-life, the median renal clearance of quinidine and the median quinidine t max were was found [8] . Other studies have concluded that disulfiram is a specific inhibitor of CYP2E1 both in vivo unchanged. No effects on the marker reactions were seen.
Effect of grapefruit juice: The median total apparent and in vitro [13, 14, 27], a finding supported by our data as disulfiram did not affect any of the other marker oral clearance of quinidine, clearance by 3-hydroxylation and by N-oxidation were significantly reduced by 15, 19 reactions. An inhibitory effect of disufiram on the metabolism of caffeine as found by Beach [28], could not and 27%, respectively. The median C max , t max and renal clearance of quinidine were unchanged. The median be confirmed here.
The effects of itraconazole on the total clearance, renal and P-glycoprotein effects as the bioavailability of quinidine is high. Despite the lack of effect on the clearance, partial clearances by 3-hydroxy-lation and Noxidation and elimination half-life of quinidine were elimination half-life of quinidine, a result which may represent a type 2 error, inhibition of hepatic CYP3A4 substantial. We found no statistically significant increase in quinidine C max , due probably to a large range of must have occurred, although inhibition of intestinal CYP3A4 and P-glycoprotein may have contributed to plasma concentrations before administration of itraconazole. The magnitude of the effects are similar to those the outcome. Administration of grapefruit juice caused minor, but found by Kaukonen et al. though they did not measure the formation clearances of either of the metabolites [16] .
still clearly significant changes in the metabolism of quinidine. While no effect was found for C max , the total Inhibition of intestinal CYP3A4 and P-glycoprotein by itraconazole would only partly account for the magnitude and partial clearances of quinidine decreased by 15-27%, and the elimination half-life of quinidine was increased of the effects seen here, and would not explain the elevated elimination half-life. As the bioavialability of by 19%. These results differ somewhat from those by Min et al. [43] , who found an increased t max and an quinidine is approximately 70% [29] and its renal clearance is relatively small, a decrease in nonrenal clearance increase in the AUC of the 3-hydroxy metabolite of quinidine following administration of a single glass of reflected by the increased elimination half-life is obvious. Inhibition of hepatic CYP3A4 by itraconazole readily grapefruit juice. No effects on the AUC of quinidine were found, a difference that may be attributable to accounts for the findings though contributions due to some degree of inhibition of P-glycopprotein and different schemes of grapefruit juice administration. In a comparative study of the effects of erythromycin and intestinal CYP3A4 cannot be excluded. We confirm ( Table 1 ) that the renal clearance of quinidine greatly grapefruit juice on the pharmacokinetics of the CYP3A4 substrate felodipine, Bailey et al.
[18] found a 93-149% exceeds glomerular filtration [30] , and this is probably due to active secretion by P-glycoprotein in the proximal increase in the AUC of felodipine. These changes are much larger than the results found for the present renal tubules [31] [32] [33] [34] . It has previously been shown that itraconazole inhibits the active tubular secretion of interaction with quinidine and the large difference in bioavailability between felodipine (15%) and quinidine digoxin [35] , another P-glycoprotein substrate, and we show here that the median renal clearance of quinidine (70%) offers a sufficient explanation. The active inhibitory components in grapefruit juice are believed to be drops from 5.2 to 2.1 l h −1 , and this interaction is most likely due to inhibition of P-glycoprotein in the proximal furanocoumarins [44] [45] [46] , and the effect of grapefruit juice is primarily an irreversible inactivation of intestinal renal tubular cells.
To our knowledge, this is the first formal pharmaco-CYP3A4 [15, 45] . Inhibition of intestinal P-glycoprotein has not been found [15] , and the lack of effect on the kinetic interaction study designed to evaluate the effect of erythromycin on the metabolism of quinidine. Case renal clearance of quinidine in this study does not support a hypothesis of inhibition of P-glycoprotein by grapefruit reports of clinically relevant interactions have previously been described [36] [37] [38] , as well as pharmacokinetic juice components. Keeping in mind the relative high bioavilability of quinidine, only minor effects of grapefruit interactions of erythromycin with other substrates of CYP3A4 [18, 39] . C max increased significantly (Table 1) , juice on the metabolism of quinidine were to be expected. The increased elimination half-life found here but surprisingly we could not demonstrate a statistically significant effect of erythromycin on the elimination halfsuggests an inhibitory effect of grapefruit juice components on hepatic CYP3A4, but the magnitude of the life of quinidine. The decrease in total clearance of quinidine and partial clearance by 3-hydroxylation and effect was marginal with the confidence limits only barely excluding zero. An inhibitory effect on hepatic CYP3A4 N-oxidation during administration of erythromycin is somewhat less than the effect found during administration is very unlikely as Lown et al. [15] could not demonstrate changes in the result of the erythromycin breath test in of itraconazole. This is consistant with in vitro CYP3A4 inhibition K i values of 0.3-2 mm [8, 40] for itraconazole healthy volunteers upon prolonged exposure to grapefruit juice. and 37-117 mm [41] for erythromycin. The increase of C max and the lack of effect on the elimination half-life Except for a 25% reduction in the caffeine metabolic ratio during grapefruit juice administration, no effects of seems to indicate that the primary effects of erythromycin on quinidine metabolism are presystemic. Erythromycin itraconazole, erythromycin or grapefruit juice on the CYP marker reactions were found. The effect of has been shown to reverse multidrug resistance in cell lines [42] , indicating an inhibitory effect on grapefruit juice confirms previous results by Fuhr et al.
[47], who found a similar reduction of caffeine clearance P-glycoprotein mediated transport. However changes in the clearance of between 33 and 50% are too large to be during grapefruit juice administration. However, no effects of grapefruit juice were seen on the pharmacoaccounted for solely by inhibition of intestinal CYP3A4 marker reaction of CYP3A4 activity.
